Information Provided By:
Fly News Breaks for June 2, 2019
CLVS
Jun 2, 2019 | 18:28 EDT
Piper Jaffray analyst Joseph Catanzaro notes that Clovis presented data from the TOPARP-B study of olaparib in mCRPC at ASCO, with data in BRCA+ patients performing in-line with data previously reported for both rucaparib and niraparib in this setting, perhaps even marginally better, though patient numbers remain small. Activity for olaparib in non-BRCA patients was underwhelming, consistent with rucaparib and olaparib, he adds. Overall, Catanzaro maintains his view that while rucaparib may be first to file in BRCA+ mCRPC, this is a modest opportunity that is becoming increasingly competitive. The analyst reiterates a Neutral rating and a $21 price target on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS